Comment on

• The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

  Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. Partin AW, et al. J Urol. 1993 Jul;150(1):110-4. doi: 10.1016/s0022-5347(17)35410-1. J Urol. 1993. PMID: 7685418
• Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

  Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Amling CL, et al. J Urol. 2001 Apr;165(4):1146-51. J Urol. 2001. PMID: 11257657
• Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.

  Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Han M, et al. J Urol. 2001 Aug;166(2):416-9. J Urol. 2001. PMID: 11458039
• High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

  Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. Zelefsky MJ, et al. J Urol. 2001 Sep;166(3):876-81. J Urol. 2001. PMID: 11490237